<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/1205"/><api:result><api:object category="publication" id="1205" last-affected-when="2024-04-14T07:33:07.847+01:00" last-modified-when="2024-04-14T07:33:07.847+01:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/1205" created-when="2010-05-17T13:47:33.48+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>2000-01-01</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="2225606" source-id="13" source-name="crossref" source-display-name="Crossref" id-at-source="10.1023/A:1008349300781" last-modified-when="2022-09-11T05:52:07.207+01:00"><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Gillespie</api:last-name><api:initials>AM</api:initials><api:first-names>AM</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Broadhead</api:last-name><api:initials>TJ</api:initials><api:first-names>TJ</api:first-names><api:separate-first-names><api:first-name>T</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Chan</api:last-name><api:initials>SY</api:initials><api:first-names>SY</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>Y</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Owen</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Farnsworth</api:last-name><api:initials>AP</api:initials><api:first-names>AP</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Sopwith</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1023/a:1008349300781</api:text><api:links><api:link type="doi" href="http://doi.org/10.1023/a:1008349300781"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1023/a:1008349300781"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>6</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Annals of Oncology</api:text></api:field><api:field name="language" type="text" display-name="Language"><api:text>en</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>735</api:begin-page><api:end-page>741</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>6</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Elsevier BV</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>http://dx.doi.org/10.1023/a:1008349300781</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>15</api:day><api:month>5</api:month><api:year>2021</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>11</api:text></api:field></api:native></api:record><api:record format="native" id="3522736" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0033752234" last-modified-when="2023-09-19T17:41:19.157+01:00"><api:citation-count>39</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Purpose: We have performed a phase I study of the cytotoxic immunoconjugate CMB-401 in women with epithelial ovarian cancer (EOC). CMB-401 is a directed chemotherapy that comprises a genetically engineered human antibody against polymorphic epithelial mucin, to which is attached covalently two to three molecules, on average, of the cytotoxic antibiotic calicheamicin. The primary objectives of this two-centre study were to identify end-organ toxicities and to establish the maximum tolerated dose (MTD). Patients and methods: Thirty-four patients aged 37 - 75 years with progressive EOC not amenable to platinum/standard therapy, and with satisfactory WHO performance status (0 - 2) were recruited. Patients had received a mean of 3.2 previous chemotherapeutic regimens with a median interval since last chemotherapy of 182 days (range 34 - 1217). Patients received up to four cycles of a dual infusion of 35 mg/m2 hCTMO1 'predose' followed by doses of CMB-401 which were increased for each cohort - a regimen which minimises drug uptake in normal tissues whilst enhancing delivery to the ovarian tumour. CMB-401 dosing commenced at 2 mg/m2 and progressed via seven cohorts to 16 mg/m2. Results: CMB-401 was generally well tolerated. However, transient fever and emesis occurred, necessitating routine prophylaxis, and increasingly significant malaise was reported as the dose increased. WHO grade 3 - 4 toxicities, irrespective of causality, included: anaemia 21%, granulocytopenia 9%, thrombocytopenia 9%, liver transaminases 3%, sepsis 3%, haemorrhage 6%, nausea/vomiting 76%; pulmonary 6%, and conscious state/somnolence 6%. The MTD was reached at 16 mg/m2. During the study four patients had a greater than 50% reduction in CA125, and three patients had radiological evidence of reduction in tumour bulk. Conclusions: CMB-401 appears to have an acceptable toxicity profile with demonstrable activity against EOC.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Gillespie</api:last-name><api:initials>AM</api:initials><api:first-names>AM</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">35481567300</api:identifier></api:identifiers></api:person><api:person><api:last-name>Broadhead</api:last-name><api:initials>TJ</api:initials><api:first-names>TJ</api:first-names><api:separate-first-names><api:first-name>T</api:first-name><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Nottingham City Hospital</api:line><api:line type="city">Nottingham</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">57854381500</api:identifier></api:identifiers></api:person><api:person><api:last-name>Chan</api:last-name><api:initials>SY</api:initials><api:first-names>SY</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>Y</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Nottingham City Hospital</api:line><api:line type="city">Nottingham</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7404255219</api:identifier></api:identifiers></api:person><api:person><api:last-name>Owen</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">57220652940</api:identifier></api:identifiers></api:person><api:person><api:last-name>Farnsworth</api:last-name><api:initials>AP</api:initials><api:first-names>AP</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>P</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="BE"><api:line type="organisation">UCB S.A.</api:line><api:line type="city">Braine-l'Alleud</api:line><api:line type="country">Belgium</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">8851356100</api:identifier></api:identifiers></api:person><api:person><api:last-name>Sopwith</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="BE"><api:line type="organisation">UCB S.A.</api:line><api:line type="city">Braine-l'Alleud</api:line><api:line type="country">Belgium</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">6603468244</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7403206142</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1023/A:1008349300781</api:text><api:links><api:link type="doi" href="http://doi.org/10.1023/A:1008349300781"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1023/A:1008349300781"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10942064</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>6</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Annals of Oncology</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>735</api:begin-page><api:end-page>741</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>1</api:day><api:month>1</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Phase I open study of the effects of ascending doses of the cytotoxic immunoconjagate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>11</api:text></api:field></api:native></api:record><api:record format="native" id="1205" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10942064" last-modified-when="2020-04-29T06:11:12.173+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>PURPOSE: We have performed a phase I study of the cytotoxic immunoconjugate CMB-401 in women with epithelial ovarian cancer (EOC). CMB-401 is a directed chemotherapy that comprises a genetically engineered human antibody against polymorphic epithelial mucin, to which is attached covalently two to three molecules, on average, of the cytotoxic antibiotic calicheamicin. The primary objectives of this two-centre study were to identify end-organ toxicities and to establish the maximum tolerated dose (MTD). PATIENTS AND METHODS: Thirty-four patients aged 37-75 years with progressive EOC not amenable to platinum/standard therapy, and with satisfactory WHO performance status (0-2) were recruited. Patients had received a mean of 3.2 previous chemotherapeutic regimens with a median interval since last chemotherapy of 182 days (range 34-1217). Patients received up to four cycles of a dual infusion of 35 mg/m2 hCTMO1 'predose' followed by doses of CMB-401 which were increased for each cohort--a regimen which minimises drug uptake in normal tissues whilst enhancing delivery to the ovarian tumour. CMB-401 dosing commenced at 2 mg/m2 and progressed via seven cohorts to 16 mg/m2. RESULTS: CMB-401 was generally well tolerated. However, transient fever and emesis occurred, necessitating routine prophylaxis, and increasingly significant malaise was reported as the dose increased. WHO grade 3-4 toxicities, irrespective of causality, included: anaemia 21%, granulocytopenia 9%, thrombocytopenia 9%, liver transaminases 3%, sepsis 3%, haemorrhage 6%, nausea/vomiting 76%; pulmonary 6%, and conscious state/somnolence 6%. The MTD was reached at 16 mg/m2. During the study four patients had a greater than 50% reduction in CA125, and three patients had radiological evidence of reduction in tumour bulk. CONCLUSIONS: CMB-401 appears to have an acceptable toxicity profile with demonstrable activity against EOC.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Gillespie</api:last-name><api:initials>AM</api:initials><api:first-names>AM</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Yorkshire Cancer Research Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK.</api:line></api:address></api:addresses></api:person><api:person><api:last-name>Broadhead</api:last-name><api:initials>TJ</api:initials><api:first-names>TJ</api:first-names><api:separate-first-names><api:first-name>T</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Chan</api:last-name><api:initials>SY</api:initials><api:first-names>SY</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>Y</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Owen</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Farnsworth</api:last-name><api:initials>AP</api:initials><api:first-names>AP</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Sopwith</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10942064</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1023/a:1008349300781</api:text><api:links><api:link type="doi" href="http://doi.org/10.1023/a:1008349300781"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1023/a:1008349300781"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>6</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Ann Oncol</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Aged</api:keyword><api:keyword scheme="mesh">Aminoglycosides</api:keyword><api:keyword scheme="mesh">Anti-Bacterial Agents</api:keyword><api:keyword scheme="mesh">Antibodies, Monoclonal</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents</api:keyword><api:keyword scheme="mesh">CA-125 Antigen</api:keyword><api:keyword scheme="mesh">Carcinoma</api:keyword><api:keyword scheme="mesh">Enediynes</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Maximum Tolerated Dose</api:keyword><api:keyword scheme="mesh">Middle Aged</api:keyword><api:keyword scheme="mesh">Ovarian Neoplasms</api:keyword><api:keyword scheme="mesh">Survival Analysis</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>England</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>735</api:begin-page><api:end-page>741</api:end-page></api:pagination></api:field><api:field name="pii" type="text" display-name="PII"><api:text>S0923-7534(19)55251-6</api:text></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>6</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>31</api:day><api:month>5</api:month><api:year>2001</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Clinical Trial</api:item><api:item>Clinical Trial, Phase I</api:item><api:item>Journal Article</api:item><api:item>Multicenter Study</api:item><api:item>Research Support, Non-U.S. Gov't</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>11</api:text></api:field></api:native></api:record><api:record format="native" id="882315" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10942064" last-modified-when="2023-12-05T18:40:09.227+00:00"><api:citation-count>21</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>&lt;h4&gt;Purpose&lt;/h4&gt;We have performed a phase I study of the cytotoxic immunoconjugate CMB-401 in women with epithelial ovarian cancer (EOC). CMB-401 is a directed chemotherapy that comprises a genetically engineered human antibody against polymorphic epithelial mucin, to which is attached covalently two to three molecules, on average, of the cytotoxic antibiotic calicheamicin. The primary objectives of this two-centre study were to identify end-organ toxicities and to establish the maximum tolerated dose (MTD).&lt;h4&gt;Patients and methods&lt;/h4&gt;Thirty-four patients aged 37-75 years with progressive EOC not amenable to platinum/standard therapy, and with satisfactory WHO performance status (0-2) were recruited. Patients had received a mean of 3.2 previous chemotherapeutic regimens with a median interval since last chemotherapy of 182 days (range 34-1217). Patients received up to four cycles of a dual infusion of 35 mg/m2 hCTMO1 'predose' followed by doses of CMB-401 which were increased for each cohort--a regimen which minimises drug uptake in normal tissues whilst enhancing delivery to the ovarian tumour. CMB-401 dosing commenced at 2 mg/m2 and progressed via seven cohorts to 16 mg/m2.&lt;h4&gt;Results&lt;/h4&gt;CMB-401 was generally well tolerated. However, transient fever and emesis occurred, necessitating routine prophylaxis, and increasingly significant malaise was reported as the dose increased. WHO grade 3-4 toxicities, irrespective of causality, included: anaemia 21%, granulocytopenia 9%, thrombocytopenia 9%, liver transaminases 3%, sepsis 3%, haemorrhage 6%, nausea/vomiting 76%; pulmonary 6%, and conscious state/somnolence 6%. The MTD was reached at 16 mg/m2. During the study four patients had a greater than 50% reduction in CA125, and three patients had radiological evidence of reduction in tumour bulk.&lt;h4&gt;Conclusions&lt;/h4&gt;CMB-401 appears to have an acceptable toxicity profile with demonstrable activity against EOC.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="GB"><api:line type="full">Yorkshire Cancer Research Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK.</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Gillespie</api:last-name><api:initials>AM</api:initials><api:first-names>AM</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Broadhead</api:last-name><api:initials>TJ</api:initials><api:first-names>TJ</api:first-names><api:separate-first-names><api:first-name>T</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Chan</api:last-name><api:initials>SY</api:initials><api:first-names>SY</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>Y</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Owen</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Farnsworth</api:last-name><api:initials>AP</api:initials><api:first-names>AP</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Sopwith</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1023/a:1008349300781</api:text><api:links><api:link type="doi" href="http://doi.org/10.1023/a:1008349300781"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1023/a:1008349300781"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1569-8041</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10942064</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>false</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>6</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Annals of oncology : official journal of the European Society for Medical Oncology</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Carcinoma</api:keyword><api:keyword scheme="mesh">Ovarian Neoplasms</api:keyword><api:keyword scheme="mesh">Aminoglycosides</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents</api:keyword><api:keyword scheme="mesh">CA-125 Antigen</api:keyword><api:keyword scheme="mesh">Antibodies, Monoclonal</api:keyword><api:keyword scheme="mesh">Anti-Bacterial Agents</api:keyword><api:keyword scheme="mesh">Survival Analysis</api:keyword><api:keyword scheme="mesh">Maximum Tolerated Dose</api:keyword><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Aged</api:keyword><api:keyword scheme="mesh">Middle Aged</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Enediynes</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>735</api:begin-page><api:end-page>741</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>6</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>15</api:day><api:month>8</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Clinical Trial</api:item><api:item>Research Support, Non-U.S. Gov't</api:item><api:item>Multicenter Study</api:item><api:item>Clinical Trial, Phase I</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>11</api:text></api:field></api:native></api:record><api:record format="native" id="2911114" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1056303354" last-modified-when="2024-04-14T07:33:07.85+01:00"><api:citation-count>38</api:citation-count><api:native><api:field name="altmetric-attention-score" type="integer" display-name="Altmetric attention score"><api:integer>3</api:integer></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Gillespie</api:last-name><api:initials>AM</api:initials><api:first-names>AM</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Yorkshire Cancer Research Department of Clinical Oncology, Weston Park Hospital Sheffield</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0614711555.42</api:identifier></api:identifiers></api:person><api:person><api:last-name>Broadhead</api:last-name><api:initials>TJ</api:initials><api:first-names>TJ</api:first-names><api:separate-first-names><api:first-name>T</api:first-name><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Department of Clinical Oncology, City Hospital Nottingham</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0670055636.33</api:identifier></api:identifiers></api:person><api:person><api:last-name>Chan</api:last-name><api:initials>SY</api:initials><api:first-names>SY</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>Y</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Department of Clinical Oncology, City Hospital Nottingham</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.014460040272.33</api:identifier></api:identifiers></api:person><api:person><api:last-name>Owen</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Yorkshire Cancer Research Department of Clinical Oncology, Weston Park Hospital Sheffield</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01164253736.14</api:identifier></api:identifiers></api:person><api:person><api:last-name>Farnsworth</api:last-name><api:initials>AP</api:initials><api:first-names>AP</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>P</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Celltech Therapeutics Slough, UK</api:line></api:address></api:addresses></api:person><api:person><api:last-name>Sopwith</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Celltech Therapeutics Slough, UK</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01306735536.83</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Yorkshire Cancer Research Department of Clinical Oncology, Weston Park Hospital Sheffield</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.014331105607.96</api:identifier></api:identifiers><api:author-types><api:author-type>corresponding</api:author-type></api:author-types></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1023/a:1008349300781</api:text><api:links><api:link type="doi" href="http://doi.org/10.1023/a:1008349300781"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1023/a:1008349300781"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10942064</api:identifier></api:identifiers></api:field><api:field name="field-citation-ratio" type="decimal" display-name="Field citation ratio"><api:decimal>3.96</api:decimal></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>6</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Annals of Oncology</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc">Clinical Research</api:keyword><api:keyword scheme="rcdc">Rare Diseases</api:keyword><api:keyword scheme="rcdc">Cancer</api:keyword><api:keyword scheme="rcdc">Orphan Drug</api:keyword><api:keyword scheme="rcdc">Ovarian Cancer</api:keyword><api:keyword scheme="hrcs-rac">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-rac">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-hc">Cancer</api:keyword><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Aged</api:keyword><api:keyword scheme="mesh">Aminoglycosides</api:keyword><api:keyword scheme="mesh">Anti-Bacterial Agents</api:keyword><api:keyword scheme="mesh">Antibodies, Monoclonal</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents</api:keyword><api:keyword scheme="mesh">CA-125 Antigen</api:keyword><api:keyword scheme="mesh">Carcinoma</api:keyword><api:keyword scheme="mesh">Enediynes</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Maximum Tolerated Dose</api:keyword><api:keyword scheme="mesh">Middle Aged</api:keyword><api:keyword scheme="mesh">Ovarian Neoplasms</api:keyword><api:keyword scheme="mesh">Survival Analysis</api:keyword></api:keywords></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Bronze OA</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>735</api:begin-page><api:end-page>741</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>6</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Elsevier</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>0.75</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>11</api:text></api:field></api:native></api:record><api:record format="native" id="241895" source-id="11" source-name="wos-lite" source-display-name="Web of Science (Lite)" id-at-source="WOS:000088219600021" last-modified-when="2024-03-14T05:58:53.337+00:00"><api:citation-count>37</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Gillespie</api:last-name><api:initials>AM</api:initials><api:first-names>AM</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Broadhead</api:last-name><api:initials>TJ</api:initials><api:first-names>TJ</api:first-names><api:separate-first-names><api:first-name>T</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Chan</api:last-name><api:initials>SY</api:initials><api:first-names>SY</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>Y</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Owen</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Farnsworth</api:last-name><api:initials>AP</api:initials><api:first-names>AP</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Sopwith</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=sheffield_elements_live&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000088219600021&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1023/A:1008349300781</api:text><api:links><api:link type="doi" href="http://doi.org/10.1023/A:1008349300781"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1023/A:1008349300781"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1569-8041</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="isidoc">335AJ</api:identifier><api:identifier scheme="pubmed">10942064</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>6</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>ANNALS OF ONCOLOGY</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>antibody</api:keyword><api:keyword>calicheamicin</api:keyword><api:keyword>CMB-401</api:keyword><api:keyword>immunotherapy</api:keyword><api:keyword>ovarian cancer</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>735</api:begin-page><api:end-page>741</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>11</api:text></api:field></api:native></api:record><api:record format="native" id="25072" source-id="3" source-name="wos" source-display-name="Web of Science" id-at-source="WOS:000088219600021" last-modified-when="2014-07-25T11:08:06.22+01:00"><api:citation-count>17</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Gillespie</api:last-name><api:initials>AM</api:initials><api:first-names>AM</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Broadhead</api:last-name><api:initials>TJ</api:initials><api:first-names>TJ</api:first-names><api:separate-first-names><api:first-name>T</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Chan</api:last-name><api:initials>SY</api:initials><api:first-names>SY</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>Y</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Owen</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Farnsworth</api:last-name><api:initials>AP</api:initials><api:first-names>AP</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Sopwith</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>6</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>ANN ONCOL</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>antibody</api:keyword><api:keyword>calicheamicin</api:keyword><api:keyword>CMB-401</api:keyword><api:keyword>immunotherapy</api:keyword><api:keyword>ovarian cancer</api:keyword><api:keyword>MONOCLONAL-ANTIBODY</api:keyword><api:keyword>BIODISTRIBUTION</api:keyword><api:keyword>MUCIN</api:keyword><api:keyword>DNA</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>735</api:begin-page><api:end-page>741</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>6</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>11</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Aminoglycosides</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Anti-Bacterial Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Antibodies, Monoclonal</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Antineoplastic Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">CA-125 Antigen</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Carcinoma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Enediynes</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Maximum Tolerated Dose</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Middle Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Ovarian Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Survival Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Carcinoma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Ovarian Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Aminoglycosides</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Antineoplastic Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">CA-125 Antigen</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Antibodies, Monoclonal</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Anti-Bacterial Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Survival Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Maximum Tolerated Dose</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Middle Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Enediynes</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Research</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Rare Diseases</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Orphan Drug</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Ovarian Cancer</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Aminoglycosides</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Anti-Bacterial Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Antibodies, Monoclonal</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Antineoplastic Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">CA-125 Antigen</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Carcinoma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Enediynes</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Maximum Tolerated Dose</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Middle Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Ovarian Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Survival Analysis</api:keyword><api:keyword origin="record-data" source="wos-lite">antibody</api:keyword><api:keyword origin="record-data" source="wos-lite">calicheamicin</api:keyword><api:keyword origin="record-data" source="wos-lite">CMB-401</api:keyword><api:keyword origin="record-data" source="wos-lite">immunotherapy</api:keyword><api:keyword origin="record-data" source="wos-lite">ovarian cancer</api:keyword><api:keyword origin="record-data" source="wos">antibody</api:keyword><api:keyword origin="record-data" source="wos">calicheamicin</api:keyword><api:keyword origin="record-data" source="wos">CMB-401</api:keyword><api:keyword origin="record-data" source="wos">immunotherapy</api:keyword><api:keyword origin="record-data" source="wos">ovarian cancer</api:keyword><api:keyword origin="record-data" source="wos">MONOCLONAL-ANTIBODY</api:keyword><api:keyword origin="record-data" source="wos">BIODISTRIBUTION</api:keyword><api:keyword origin="record-data" source="wos">MUCIN</api:keyword><api:keyword origin="record-data" source="wos">DNA</api:keyword><api:keyword scheme="for" origin="issn-inferred">1112 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Oncology &amp; Carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3202 Clinical sciences</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3211 Oncology and carcinogenesis</api:keyword></api:keywords></api:all-labels><api:journal issn="0923-7534" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567" title="Annals of Oncology"><api:records><api:record source-name="summary"><api:title>Annals of Oncology</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/1205/relationships"/></api:object></api:result></api:response>